Nuvation Bio (NUVB) Bounces Back 12% on Impressive Clinical Trial Result

Core Insights - Nuvation Bio Inc. (NYSE:NUVB) experienced a significant rebound of 12.05% to close at $8.37 following positive results from its phase 2 study on Safusidenib for treating a type of brain tumor [1] - The study achieved its primary endpoint with an objective response rate of 44.4% [1] - The results were published in the journal of Neuro-Oncology, highlighting the potential of Safusidenib to improve quality of life by delaying chemoradiation [3] Study Details - The clinical trial evaluated 27 patients with IDH1-mutant grade 2 gliomas who had not received prior anticancer therapy, except for resection or biopsy [2] - Side effects were primarily mild to moderate, with five patients experiencing grade 3 or greater treatment-related adverse events, and no grade 5 events reported [2] Management Commentary - David Hung, President and CEO of Nuvation Bio Inc., emphasized the impressive response rate and prolonged progression-free survival demonstrated by Safusidenib, suggesting its potential benefits for patients [3]